Literature DB >> 30498936

Clinical Application of Three-Dimensionally Printed Biomaterial Polycaprolactone (PCL) in Augmentation Rhinoplasty.

Young Jin Park1, Jong Hyun Cha2, Sa Ik Bang3, So Young Kim4.   

Abstract

BACKGROUND: This clinical study aimed to investigate the safety and surgical outcome of three-dimensionally (3D) fabricated polycaprolactone (PCL) mesh in rhinoplasty. In particular, this study explored how a 3D-printed PCL mesh performs as a bioabsorbable scaffold after a long period following implantation.
METHODS: A retrospective review of 101 patients who received primary or secondary rhinoplasty with a PCL mesh was performed. Patient demographics and surgery-related outcomes were examined. Clinical efficacy and safety were evaluated using the Global Aesthetic Improvement Scale at postoperative 18 months. From two revisional cases, a biopsy specimen of implanted PCL was acquired and histopathological analysis was performed.
RESULTS: Of all the patients, 98.0% showed no postoperative infection-related foreign body reaction or distinct abnormal reaction, and the implants were observed to maintain long-term efficacy until 18-month follow-up. In patients who received spreader grafts, significant differences between preoperative and postoperative Cottle sign scores were found. Histopathological analysis showed features of adjacent tissue infiltration into pores of the PCL mesh and regeneration of neo-cartilaginous tissue and collagen around the mesh 20 months after implantation.
CONCLUSION: This study demonstrates that a novel biodegradable PCL mesh with a 3D structure is a safe and effective material for corrective rhinoplasty because it is easy to use and capable of maintaining its volume in the long term without foreign body response. This biocompatible material will have a wide range of applications as the most suitable alternative to nonabsorbable materials in rhinoplasty and reconstruction surgeries, such as fashioning spreader grafts and septal extension grafts. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

Entities:  

Keywords:  3D PCL mesh; Alloplastic implant; Rhinoplasty

Mesh:

Substances:

Year:  2018        PMID: 30498936     DOI: 10.1007/s00266-018-1280-1

Source DB:  PubMed          Journal:  Aesthetic Plast Surg        ISSN: 0364-216X            Impact factor:   2.326


  6 in total

1.  Biodegradable implants for orbital wall fracture reconstruction.

Authors:  Hyeon Uk Jang; So Young Kim
Journal:  Arch Craniofac Surg       Date:  2020-04-20

2.  Validation of the optimal scaffold pore size of nasal implants using the 3-dimensional culture technique.

Authors:  Jeoung Hyun Nam; So Yun Lee; Galina Khan; Eun Soo Park
Journal:  Arch Plast Surg       Date:  2020-07-15

3.  Evaluation of the Usability of a Low-Cost 3D Printer in a Tissue Engineering Approach for External Ear Reconstruction.

Authors:  Constanze Kuhlmann; Jana C Blum; Thilo L Schenck; Riccardo E Giunta; Paul Severin Wiggenhauser
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

4.  Clinical Application of 3D-Printed Patient-Specific Polycaprolactone/Beta Tricalcium Phosphate Scaffold for Complex Zygomatico-Maxillary Defects.

Authors:  Woo-Shik Jeong; Young-Chul Kim; Jae-Cheong Min; Ho-Jin Park; Eun-Ju Lee; Jin-Hyung Shim; Jong-Woo Choi
Journal:  Polymers (Basel)       Date:  2022-02-14       Impact factor: 4.329

5.  Clinical Application of Three-Dimensional Printing of Polycaprolactone/Beta-Tricalcium Phosphate Implants for Cranial Reconstruction.

Authors:  Hojin Park; Jong Woo Choi; Woo Shik Jeong
Journal:  J Craniofac Surg       Date:  2022-03-09       Impact factor: 1.172

6.  Soft, Formstable (Co)Polyester Blend Elastomers.

Authors:  Axel T Neffe; Victor Izraylit; Paul J Hommes-Schattmann; Andreas Lendlein
Journal:  Nanomaterials (Basel)       Date:  2021-06-01       Impact factor: 5.076

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.